Karyopharm Therapeutics Inc

NASDAQ:KPTI  
8.39
+0.25 (+3.07%)
Products

Karyopharm Receives EC's Conditional Marketing Authorization For Nexpovio In Combination With Dexamethasone

Published: 03/29/2021 18:22 GMT
Karyopharm Therapeutics Inc (KPTI) - Karyopharm Receives Conditional Marketing Authorization From the European Commission for Nexpovio® (selinexor) in Combination With Dexamethasone for the Treatment of Adult Patients With Relapsed and Or Refractory Multiple Myeloma.
Karyopharm Therapeutics Inc - Second European Regulatory Filing Based on Phase 3 Boston Data Expected by April 2021.